Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1.
作者信息
Mykytyn Anna Z, Rosu Miruna E, Kok Adinda, Rissmann Melanie, van Amerongen Geert, Geurtsvankessel Corine, de Vries Rory D, Munnink Bas B Oude, Smith Derek J, Koopmans Marion P G, Lamers Mart M, Fouchier Ron A M, Haagmans Bart L
机构信息
Viroscience Department, Erasmus Medical Center, Rotterdam 3015CN, Netherlands.
Viroclinics Biosciences BV, Viroclinics Xplore, Schaijk, Netherlands.
出版信息
Lancet Microbe. 2023 May;4(5):e294-e295. doi: 10.1016/S2666-5247(22)00384-6. Epub 2023 Jan 16.
Abstract
摘要
相似文献
1
Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1.
Lancet Microbe. 2023 May;4(5):e294-e295. doi: 10.1016/S2666-5247(22)00384-6. Epub 2023 Jan 16.
2
An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB.
Cell Rep Med. 2023 Apr 18;4(4):100991. doi: 10.1016/j.xcrm.2023.100991. Epub 2023 Mar 21.
3
Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2.
Signal Transduct Target Ther. 2023 Mar 15;8(1):125. doi: 10.1038/s41392-023-01391-x.
4
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
Cell. 2023 Jan 19;186(2):279-286.e8. doi: 10.1016/j.cell.2022.12.018. Epub 2022 Dec 14.
5
Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages - United States, January 2022-May 2023.
MMWR Morb Mortal Wkly Rep. 2023 Jun 16;72(24):651-656. doi: 10.15585/mmwr.mm7224a2.
6
Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
J Med Virol. 2023 Jul;95(7):e28932. doi: 10.1002/jmv.28932.
7
Global threat from novel SARS-CoV-2 variants, BF.7, XBB.1.5, BQ.1, and BQ.1.1: variants of concern?
Hum Cell. 2023 May;36(3):1218-1221. doi: 10.1007/s13577-023-00903-9. Epub 2023 Mar 31.
8
Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.
Antiviral Res. 2023 Jul;215:105638. doi: 10.1016/j.antiviral.2023.105638. Epub 2023 May 18.
9
Wastewater surveillance of SARS-CoV-2 variants in October-November 2022 in Italy: detection of XBB.1, BA.2.75 and rapid spread of the BQ.1 lineage.
Sci Total Environ. 2023 May 15;873:162339. doi: 10.1016/j.scitotenv.2023.162339. Epub 2023 Feb 21.
10
Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy.
Acta Trop. 2023 Dec;248:107042. doi: 10.1016/j.actatropica.2023.107042. Epub 2023 Oct 18.
引用本文的文献
1
Cross-neutralization of human sera with diverse SARS-CoV-2 omicron exposure histories, 2022-2024: Evidence of immune heterogeneity.
One Health. 2025 Jul 17;21:101145. doi: 10.1016/j.onehlt.2025.101145. eCollection 2025 Dec.
2
Integrated Analysis of the 2022 SARS-CoV-2 Omicron Lineage Replacement Dynamics in Connecticut, US.
Viruses. 2025 Jul 21;17(7):1020. doi: 10.3390/v17071020.
3
Back-projection improves inference from sparsely sampled genomic surveillance data.
bioRxiv. 2025 Jul 1:2025.06.29.662219. doi: 10.1101/2025.06.29.662219.
4
Longitudinal assessment of COVID-19 vaccine immunogenicity in people with HIV stratified by CD4+ T-cell count in the Netherlands: A two-year follow-up study.
PLoS One. 2025 May 19;20(5):e0323792. doi: 10.1371/journal.pone.0323792. eCollection 2025.
5
Genome data artifacts and functional studies of deletion repair in the BA.1 SARS-CoV-2 spike protein.
Virus Evol. 2025 Mar 11;11(1):veaf015. doi: 10.1093/ve/veaf015. eCollection 2025.
6
SARS-CoV-2 serotyping based on spike antigenicity and its implications for host immune evasion.
EBioMedicine. 2025 Apr;114:105634. doi: 10.1016/j.ebiom.2025.105634. Epub 2025 Mar 12.
7
Longitudinal humoral immunity against SARS-CoV-2 Spike following infection in individuals from Cameroon.
Virology. 2025 Apr;605:110467. doi: 10.1016/j.virol.2025.110467. Epub 2025 Feb 25.
8
Nonhuman primate antigenic cartography of SARS-CoV-2.
Cell Rep. 2025 Jan 28;44(1):115140. doi: 10.1016/j.celrep.2024.115140. Epub 2025 Jan 3.
9
Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.
Nat Commun. 2024 Dec 30;15(1):10778. doi: 10.1038/s41467-024-55087-z.
10
Serodynamics: A primer and synthetic review of methods for epidemiological inference using serological data.
Epidemics. 2024 Dec;49:100806. doi: 10.1016/j.epidem.2024.100806. Epub 2024 Nov 30.
本文引用的文献
1
Mapping SARS-CoV-2 antigenic relationships and serological responses.
Science. 2023 Oct 6;382(6666):eadj0070. doi: 10.1126/science.adj0070.
2
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.
Nat Med. 2023 Feb;29(2):344-347. doi: 10.1038/s41591-022-02162-x. Epub 2022 Dec 6.
3
Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history.
Cell Host Microbe. 2022 Dec 14;30(12):1745-1758.e7. doi: 10.1016/j.chom.2022.10.012. Epub 2022 Oct 21.
4
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.
Science. 2022 Nov 11;378(6620):619-627. doi: 10.1126/science.adc9127. Epub 2022 Oct 20.
5
Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron.
Immunity. 2022 Sep 13;55(9):1725-1731.e4. doi: 10.1016/j.immuni.2022.07.018. Epub 2022 Aug 5.
6
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct.
Sci Immunol. 2022 Sep 23;7(75):eabq4450. doi: 10.1126/sciimmunol.abq4450.
Zotero 插件